Additionally, selpercatinib was evaluated in 42 patients with RET-fused tumors of different histologies other than lung and thyroid; durable antitumor activity across different tumor subtypes was observed, with only minor adverse effects [927]. This evidence concerns the gene RET and neoplasm.